Patent RU-2166938-C1 (RU)
Inventor: PROMZELEVA N V
IPC: G01N33/68
Filed: 1999-11-01
Granted: 2001-05-20
Abstract: FIELD: medicine. SUBSTANCE: method involves applying adjuvant therapy by selecting chemotherapy using nonspecific tumor marker application data. α2-glycoprotein associated with pregnancy is used as nonspecific mammary gland carcinoma marker. Its contents is determined before applying complex treatment. The contents level is compared to α2- glycoprotein concentration level corresponding to each disease development stage. No polychemotherapy is administered after performing surgical treatment of mammary gland carcinoma IA and α2-glycoprotein value being less than 0.017 g/l and mammary gland carcinoma IIA and α2- glycoprotein value being less than 0.022 g/l. If first stage mammary gland carcinoma is the case and α- glycoprotein value 0.017 g/l or mammary gland carcinoma IIA and α2-glycoprotein value being less than 0.022 g/l and α2-glycoprotein value growing dynamically by 25% during two months after applying surgical treatment taking into account age factor and ovarian and menstrual function condition, four polychemotherapy courses are administered to young and aged women with retained ovarian and menstrual function with 1 month long pause. Course schedule is as follows. Cyclophosphate 100mg/m 2  is intramuscularly administered from the first to the eighth day, metatrexate 40 mg/m 2  intravenously administered at the first and the eighth day, 5- fluorouracyl 600mg/m 2  at the first and the eighth day and the aged patients in menopause period are treated with hormone therapy with antiestrogen drugs like tacmoxiphene at a dose of 20 g daily during 1 year. IIB, IIIA, IIIB-stage mammary gland carcinoma cases when α2- glycoprotein value 0.031 g/l, α2-glycoprotein value <0.038 g/l, α2-glycoprotein value 0.044 g/l, respectively, are treated with 6 courses of polychemotherapy with 1 month long pause. Course schedule is as follows. Cyclophosphate 100mg/m 2  is intramuscularly administered from the first to the eighth day, metatrexate 40 mg/m 2  intravenously administered at the first and the eighth day, 5-fluorouracyl 600mg/m 2  at the first and the eighth day. Reduced level of α2-glycoprotein by 25% during the treatment to the twelfth month after the operation shows favorable disease development course requiring no continuation of the treatment at the second year of patient observation. Background values exceeding the corresponding value, chemotherapy is added by hormone therapy with antiestrogen drugs like tacmoxiphene at a dose of 20 g daily during 1 year. Initially normal α2- glycoprotein value being increased by 25% and more, 6 courses of polychemotherapy are carried out with hormone therapy using antiestrogen drugs like tacmoxiphene at a dose of 20 g daily during 2 years. IIB, IIIA, IIIB-stage mammary gland carcinoma cases when α2-glycoprotein value is normal or increases by 25% during two months, the following FAG therapy course is to be administered. 5-fluorouracyl 500mg/m 2  is given at the first and the eighth day, adriamycin 50 mg/m 2  (the eighth day, cyclophosphane at a dose of 500 mg/m 2  at the first and the eighth day and hormone therapy using antiestrogen drugs like tacmoxiphene at a dose of 20 g daily during 2 years are to be applied. α2-glycoprotein value growing to the end of the first year after the surgical operation being done on the background of 6 courses of chemotherapy and hormone therapy with tamoxiphene by 50% and higher, additional hormone therapy is applied with progestines. The patients receive tamoxiphene at a dose of 20 mg per day and Megey at a dose of 160 mg per day. EFFECT: enhanced effectiveness of treatment.